SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

The culprit for the underperformance is where things get interesting. Per management, during the second quarter, wholesalers of its blockbuster drugs for type 2 diabetes and obesity, Mounjaro and ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless hype ...

Could Eli Lilly make millionaires out of investors at current levels? Let's find out. Eli Lilly developed a medicine called ...

The FDA added the warning to most of the drugs on Nov. 1, according to the agency’s website. The warning applies to GLP-1 ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...